IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4770
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$54M
C. Russell Trenary
Outlook Therapeutics, Inc. focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$OTLK Outlook Therapeutics, Inc. | 25 | 27 | 11 | 3 | - | - | 71.9% | -247.6% | 70.8% | -1046.2% | -1338.8% | - | 0.0% | - | $54M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Outlook Therapeutics, Inc. (OTLK) receives a "Avoid" rating with a composite score of 25.0/100. It ranks #4770 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for OTLK.
View All RatingsROIC -41.7% vs WACC 4.6% (spread -46.3%)
GM 71% vs sector 44%, OM -1046% vs sector 3%
Capital turnover -0.05x
Rev growth N/A, 10yr history
Interest coverage -273.2x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Outlook Therapeutics, Inc. (OTLK) as Avoid with a composite score of 25.0/100 at a current price of $0.43. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Outlook Therapeutics, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 25.0/100 places it at rank #4770 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 71% signal strong pricing power.
Returns on equity of 71.9% exceed cost of capital.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Outlook Therapeutics, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Outlook Therapeutics, Inc. with an Avoid rating, assigning a composite score of 25.0/100 and 1 out of 5 stars. Ranked #4770 of 7,333 stocks, OTLK falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
OTLK's quality score of 27/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 71.9% (sector avg: -1.9%), gross margins of 70.8% (sector avg: 44.1%), net margins of -1338.8% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
OTLK registers a value score of just 11/100, suggesting the stock trades at a significant premium to its fundamental metrics. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Outlook Therapeutics, Inc.'s investment score of 19/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -247.6% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Outlook Therapeutics, Inc. is experiencing notably weak momentum with a score of just 3/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 0.74 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
OTLK's stability score of 33/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.74. Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
OTLK carries a short interest score of 71/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include micro-cap liquidity risk. At $54M market cap (micro-cap), Outlook Therapeutics, Inc. offers reasonable institutional liquidity.
Outlook Therapeutics, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4770 of 7,333 overall (35th percentile). Key comparisons include ROE of 71.9% exceeding the -1.9% sector median and operating margins of -1046.2% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While OTLK currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (3) would have the largest impact on the composite score.
ROE 3883% BELOW SECTOR MEDIAN
Gross Margin 61% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 41781% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab gamma) in SwitzerlandPartnership advances European commercial expansion strategy, with LYTENAVA™ (bevacizumab gamma) expected to launch in Switzerland in 2027 ISELIN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused
U.S. stock futures rose on the first trading day of 2026, with the S&P 500 and Nasdaq 100 gaining in premarket trading. Key movers included Baidu jumping 12.2% on a spinoff announcement, Rubico surging 16.8% following an acquisition deal, while Outlook Therapeutics plummeted 56.5% after an FDA rejection and Intelligent Bio Solutions dropped 23.4% on a private placement announcement. Analysts predict modest 3-5% gains for 2026 after a record-breaking 2025.
Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. CION Investment The Trade: CION Investment Corporation (NYSE: CION) Co-Chairman & Co-CEO Mark Gatto acquired ...
Oncobiologics (OTLK) delivered earnings and revenue surprises of -26.95% and -131.38%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Outlook Therapeutics, a biopharmaceutical company, announced the pricing of a $13.0 million public offering of common stock and accompanying warrants. The company plans to use the net proceeds for working capital and general corporate purposes.